Methods for treatment of melanoma
AssigneesChildren's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
InventorsLeonard Zon, Richard M. White
Life of this patent
Estimating the term…
Abstract
Embodiments of the present invention are directed to methods for treatment of melanoma using an inhibitor of dihydroorotate dehydrogenase (DHODH) and to combination therapies that involve administering to a subject an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)), as well as an inhibitor of dihydroorotate dehydrogenase (DHODH). Assays for identifying compounds useful for the treatment of melanoma are also provided. The methods comprise screening for compounds or agents that inhibit neural crest progenitor formation in a zebra fish model of melanoma.
Claims14
A method for treating melanoma in a subject comprising administering to a subject in need thereof a therapeutically effective amount of an inhibitor of dihydroorotate dehydrogenase (DHODH), wherein the inhibitor of DHODH is selected from the group consisting of:
- C19H14F2N2O3;
- C18H13F6NO4;
- C19H16F3NO4;
- C19H10F5NO4S;
- C19H14FNO4S;
- C20H15F4NO4;
- C19H17NO4;
- C20H17F2NO4;
- and C20H18FNO4.
The method of 2, wherein the inhibitor of dihydroorotate dehydrogenase is C19H14F2N2O3.
The method of 2, wherein the inhibitor of dihydroorotate dehydrogenase is C19H14F2N2O3.
A pharmaceutical composition for treatment of melanoma comprising a combination of an inhibitor of dihydroorotate dehydrogenase (DHODH) and an inhibitor of oncogenic BRAF, wherein the inhibitor of DHODH is selected from the group consisting of:
- C19H14F2N2O3;
- C18H13F6NO4;
- C19H16F3NO4;
- C19H10F5NO4S;
- C19H14FNO4S;
- C20H15F4NO4;
- C19H17NO4;
- C20H17F2NO4;
- and C20H18FNO4.
Dependencies are inferred from the claim text.